文献速递骨质疏松与代谢性骨病小儿骨科

成骨不全VI型的长期随访研究

Long-term follow-up in osteogenesis imperfecta type VI.
PubMed 文献 · Osteoporos Int · 2017-07-09

本回顾性研究纳入13例成骨不全VI型患者,发现静脉双膦酸盐治疗与腰椎面积骨密度增加、最终身高z评分较高及椎体重塑相关;未治疗者儿童期骨密度不增、6至8岁后纵向生长似停滞。不同SERPINF1突变类型表型相似。

要点

  • 静脉双膦酸盐治疗与腰椎面积骨密度增加及压缩椎体部分重塑相关。
  • 6岁前开始双膦酸盐治疗者比生长期间较晚治疗者更高。
  • 尽管使用双膦酸盐,下肢骨折仍频繁,达到最终身高者均存在脊柱侧弯。

核心结论

  • 生长期间接受静脉双膦酸盐治疗的成骨不全VI型患者腰椎面积骨密度增加、最终身高z评分较高,并出现椎体部分重塑。
  • 成骨不全VI型显然需要更有效的治疗方式。

研究设计与样本

  • 本回顾性研究对13例成骨不全VI型个体进行了病历回顾。

主要发现

  • 未治疗时,腰椎面积骨密度在儿童期不增加,纵向生长在6至8岁后似停滞。
  • 不同SERPINF1突变类型个体的表型相似。
  • 静脉双膦酸盐治疗与腰椎面积骨密度增加及压缩椎体部分重塑相关。
  • 6岁前开始双膦酸盐治疗的患者比生长期间较晚接受治疗的患者更高。
  • 尽管接受双膦酸盐治疗,下肢骨折仍频繁;达到最终身高的所有患者均存在脊柱侧弯;大多数患者活动能力受限。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This retrospective study on long-term outcomes in osteogenesis imperfecta type VI found that patients who received intravenous bisphosphonate treatment had an increase in lumbar spine areal bone mineral density, a higher final height z-score, and some reshaping of vertebral bodies. INTRODUCTION: Osteogenesis imperfecta (OI) type VI is an ultra-rare bone fragility disorder caused by recessive mutations in SERPINF1. Here, we describe long-term outcomes in OI type VI and compare the clinical phenotypes caused by different types of SERPINF1 mutations. METHODS: This study includes a retrospective chart review of 13 individuals with OI type VI. RESULTS: In the absence of therapy, lumbar spine areal bone mineral density (BMD) did not increase during childhood and longitudinal growth seemed to stall after the age of 6 to 8 years. The phenotype was similar between individuals with different types of SERPINF1 mutations. Intravenous bisphosphonate treatment was associated with an increase in lumbar spine areal BMD and some reshaping of compressed vertebral bodies. Patients who had started bisphosphonate treatment early (before the age of 6 years) were taller than patients who had received bisphosphonate treatment later during their growing years. Lower extremity fractures were frequent despite bisphosphonate treatment and scoliosis was present in all patients who had reached the final height. Most patients had restricted mobility. In four patients, intravenous bisphosphonate treatment was eventually substituted by subcutaneous injections of denosumab, without clear changes in the clinical picture. CONCLUSIONS: Patients with OI type VI who received intravenous bisphosphonate treatment during growth had an increase in lumbar spine areal BMD, a higher final height z-score, and presented some reshaping of vertebral bodies. More effective treatment modalities are clearly required in OI type VI.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Trejo P, Palomo T, Montpetit K, et al. Long-term follow-up in osteogenesis imperfecta type VI. Osteoporos Int. 2017. PMID: 28689307. doi:10.1007/s00198-017-4141-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。